AKCİĞER KANSERİNDE UYGULANAN KEMOTERAPİYE BAĞLI TOKSİSİTE
Bu çalışmanın amacı, 2004-2010 yılları arasında akciğer kanseri nedeniyle birinci hat kemoterapi alan olgularda tercih edilen kemoterapi kombinasyonlarını ve gelişebilecek kısa dönem yan etkileri ortaya koymaktır. Hastalar retrospektif olarak çalışmaya alındı. Yaş, cinsiyet, hastalık evresi, performans düzeyi (ECOG skoru), tümör hücre tipi, planlanan kemoterapi uygulaması, birinci kür sonrası oluşan toksisiteleri kaydedildi. Toksisite değerlendirmeleri CTCAE kriterlerine göre yapıldı. Çalışmaya toplam 803 hasta alındı. En sık rastlanan tümör hücre tipleri, küçük hücreli dışı, skuam öz, adenokarsinom ve küçük hücreli karsinomdu. En fazla tercih edilen kemoterapi kombinasyon rejimleri olarak da Cisplatin+Gemsitabine, Cisplatin+Etoposide ve Cisplatin+Dosetaksel göze çarpmaktaydı. Bütün rejimler göz önüne alındığında en sık rastlanan toksisiteler anemi ve nötropeni gibi hematolojik toksisitelerdi. Cisplatin bazlı rejim alanların %40'ında, Carboplatin bazlı rejim alanların da %39'unda yan etki gözlenmedi. Akciğer kanserli hastalarda kemoterapi uygulamaları sırasında, özellikle kısa dönem toksisiteler açısından anemi, nötropeni ve bulantı-kusma akılda tutulmalıdır. Kemoterapi uygulanacak hastaların seçimi sırasında bu yan etki profillerine göre fayda risk analizi yapılmalı ve ilaç kombinasyonları buna göre oluşturulmalıdır.
TOXICITIES DUE TO CHEMOTHERAPY IN LUNG CANCER
The aim of this study was to evaluate the chemotherapy combination choices and short term toxicities in lung cancer patients who had first line chemotherapy between 2004 and 2010. Patients were enrolled retrospectively. Age, gender, disease stage, performance status (ECOG score), histologic type of the tumour, chemotherapy choice and toxicities were recorded. Evaluation of the toxicites were done according to the CTCAE criteria. A total number of 803 patients were included in the study. The most common tumour types were nonsmall cell, squamous, adenocarcinoma and small cell carcinoma. The most common choice of chemotherapy combinations were Cisplatin+ Gemsitabine, Cisplatin+Etoposide and Cisplatin+ Docetaxel respectively. When all the chemotherapy regimes were evaluated, the most common toxicites were hematologic ones such as anemia and neutropenia. No side effects were observed in 40% of patients who had Cisplatin based combinations and 39% of patients who had Carboplatin based combinations. Short term toxicites such as anemia, neutropenia and nausea must be kept in mind in lung cancer patients who will have chemotherapy. Benefit and risks should be analysed carefully and selection of chemotherapy combinations and patients should be done according to these toxiciy profiles.
___
- 1. Abal› H, Zengin N. Akci¤er kanseri kemoterapisinde
miyelotoksisite yönetimi. Gülhan M,
Turay ÜY (eds). Akci¤er Kanserinde Destek
Tedavisi. Sentez Matbaac›l›k, Ankara, 2009;
155-61.
- 2. Yurdakul AS. Kemoterapiye ba¤l› bulant› ve
kusmalarda yaklafl›m. Akci¤er ve Plevra
Maligniteleri Tedavisi. Göksel T, Özlü T (eds).
Sentez Matbaac›l›k, Ankara, 2008; 184-95.
- 3. WHO Toxicity Grading Scale for Determining
The Severity of Adverse Events. http://www.
icssc.org/Documents/Resources/
AEManual2003AppendicesFebruary_06_200
3%20final.pdf.
- 4. Helbekkmo N, Aasebo U, Sundstrom SH, et al.
Treatment outcome in performance status 2
advanced NSCLC patients administered
platinum-based combination chemotherapy.
Lung Cancer 2008; 62(2): 253-60.
- 5. Jensen LH, Osterlind CK. Rytter, Randomized
cross-over study of patient preference for oral
or intravenous vinorelbine in combination
with carboplatin in the treatment of advanced
NSCLC. Lung Cancer 2008; 62(1): 85-91.
- 6. Pepe C, Hasan B, Winton TL, et al. Adjuvant
vinorelbine and cisplatin in elderly patients:
National Cancer Institute of Canada and
Intergroup Study JBR.10. J Clin Oncol, 2007;
25(12): 1553-61.
- 7. Gebbia V, Galetta D, Lorusso V, et al. Cisplatin
plus weekly vinorelbine versus cisplatin plus
vinorelbine on days 1 and 8 in advanced
non-small cell lung cancer: a prospective
randomized phase III trial of the G.O.I.M.
(Gruppo Oncologico Italia Meridionale). Lung
Cancer 2008; 61(3): 369-77.
- 8. Helbekkmo N, Sundstrom SH, Aasebo U, et
al. Vinorelbine/carboplatin vs gemcitabine/similar efficacy, but different impact of toxicity.
Br J Cancer 2007; 97(3): 283-9.
- 9. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatinversus
carboplatin-based chemotherapy in
first-line treatment of advanced non-smallcell
lung cancer: an individual patient data
meta-analysis. J Natl Cancer Inst 2007; 99
(11): 847-57.
- 10. Schiller JH, Harrington D, Belani CP, et al.
Comparison of four chemotherapy regimens
for advanced non-small-cell lung cancer.
N Engl J Med 2002; 346(2): 92.
- 11. Casas FN. Vinolas, Toxicity of small cell lung
cancer treatment. Hematol Oncol Clin North
Am 2004; 18(2): 461-81.
- 12. Zatloukal P, Petruzelka L, Zemanova M, et al.
Gemcitabine plus cisplatin vs. gemcitabine
plus carboplatin in stage IIIb and IV nonsmall
cell lung cancer: a phase III randomized
trial. Lung Cancer 2003; 41(3): 321-31.
- 13. Winton T, Livingston R, Johnson D, et al.
Vinorelbine plus cisplatin vs. observation in
resected non-small-cell lung cancer. N Engl J
Med 2005; 352(25): 2589-97.
- 14. Hardy D, Cormier JN, Xing Y, et al. Chemotherapy-associated
toxicity in a large cohort
of elderly patients with non-small cell lung
cancer. J Thorac Oncol 2010; 5(1): 90-8.